Lead Product(s) : Bromfenac
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches Bromfenac Ophthalmic Solution, 0.075% in US
Details : BromSite-Generic (bromfenac) acts by inhibiting Cox-1 and 2. It is indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.
Product Name : BromSite-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : Bromfenac
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
